Cancer patients are at increased risk of deep venous thrombosis and pulmonary embolism, collectively termed venous thromboembolism (VTE). Risk assessment scores for VTE in cancer patients have been previously developed by the groups of Khorana and Vienna CATS. However, routine thromboprophylaxis for ambulatory cancer patients based on these scores is currently not recommended. In the investigators prospective, observational cohort study, the investigators aim to identify cancer patients at high risk for VTE based on clinical characteristics, coagulation biomarkers and the coagulant activity of tissue factor bearing microparticles.
Study Type
OBSERVATIONAL
Enrollment
900
Hopital Louis Mourier
Colombes, Île-de-France Region, France
Hospital D'Annunziata
Chieti, Italy
Instituto Nacional de Cancerología
Mexico City, Mexico
Slotervaart hospital
Amsterdam, North Holland, Netherlands
VU medical center
Amsterdam, North Holland, Netherlands
Academic Medical Center
Amsterdam, North Holland, Netherlands
University Medical Center Groningen
Groningen, Provincie Groningen, Netherlands
venous thromboembolism
Objectively confirmed asymptomatic or symptomatic deep venous thrombosis or pulmonary embolism
Time frame: 6 months after enrollment
all-cause mortality
Time frame: 6 months after enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.